Diagnostic Performance of a Combined KLK2, miR-21, PSA, CRP, Albumin, AGR, and GGT Biomarker Panel for Distinguishing Prostate Cancer from Benign Prostatic Hyperplasia in Nigerian Men
In a study of Nigerian men, while a combined panel of KLK2, miR-21, CRP, albumin, AGR, and GGT with PSA did not improve diagnostic accuracy over PSA alone for distinguishing prostate cancer from benign prostatic hyperplasia, the findings suggest that a reduced model incorporating locally available markers may still offer feasibility value for specific patient subgroups.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of men around the world, a simple blood test serves as the first line of defense against a silent threat: prostate cancer. The test measures a protein called prostate-specific antigen, or PSA, which is produced by the prostate gland. When the prostate is healthy, PSA levels are low. When the gland is enlarged by a common, non-cancerous condition known as benign prostatic hyperplasia, or BPH, or when it is affected by cancer, those levels rise. This creates a difficult medical puzzle. Because both the harmless enlargement and the dangerous cancer cause the same protein to spike, a high PSA result often leads to unnecessary anxiety and invasive biopsies, especially in African populations where baseline levels can naturally run higher. Doctors have long searched for a way to tell these two conditions apart without cutting into the patient, hoping to find a second clue hidden in the blood that could confirm whether a man truly has cancer or simply an enlarged gland.
A team of researchers in Nigeria recently tackled this challenge by testing a new strategy. They gathered blood samples from ninety men attending four hospitals in Abuja. The group was divided into three equal parts: thirty men with histologically confirmed prostate cancer, thirty men with benign prostatic hyperplasia, and thirty healthy men with no prostate issues. The scientists did not rely on the standard PSA test alone. Instead, they looked for a combination of seven different signals in the blood. Alongside the familiar PSA, they measured a related protein called KLK2, a tiny genetic messenger known as miR-21, a marker of body-wide inflammation called CRP, and several other standard blood chemistry values. Their goal was to see if this complex mix of markers could act as a more precise filter than PSA alone, correctly identifying the men with cancer while sparing those with benign conditions from further procedures.
The results of this investigation were surprising and clear. When the researchers analyzed the data, they found that the single, traditional PSA test was already performing at a near-perfect level for this specific group of patients. It correctly identified the men with cancer with an accuracy that was statistically indistinguishable from a perfect score. In fact, when the team tried to improve upon this by adding the other six markers into a combined formula, the accuracy did not get better; it actually became slightly worse. The complex panel of seven markers failed to outperform the simple, single PSA test. This outcome suggests that for men in this region who present with advanced disease, the PSA level is already so high and distinct that adding more data points does not help distinguish the cancer from the benign condition any better than the first test already does.
However, the study did not find that the other markers were useless. Two of the additional signals, KLK2 and CRP, showed a genuine ability to tell the difference between cancer and benign enlargement when looked at directly. They rose significantly in the men with cancer compared to those with the benign condition. The researchers noted that while these markers carry real diagnostic information, they are so closely linked to the PSA levels that they do not add new, independent power when used together in a crowded model. It is as if the new markers are simply echoing the same loud signal that the PSA test is already shouting. Because the PSA test was already so effective at separating the two groups in this late-presenting cohort, there was very little room for the other markers to add value.
Despite the fact that the combined panel did not beat the single test, the researchers did not stop there. They built a simplified, practical tool based on the most promising markers: PSA, KLK2, miR-21, CRP, and the patient's age. This tool was designed to be used with the standard laboratory equipment already available in Nigerian hospitals, requiring no expensive new technology. They turned this model into a visual chart, known as a nomogram, which allows a doctor to plug in a patient's numbers and get a calculated probability of cancer. While this tool showed strong ability to distinguish between the groups within the study, the authors are careful to state that it is a feasibility test. It proves that such a model can be built and used with local resources, but it has not yet been proven to work better than the standard test in a wider population or in men with lower, more ambiguous PSA levels.
The study concludes that for the men in this specific Nigerian cohort, the traditional PSA test remains the most powerful single tool for distinguishing cancer from benign enlargement. The idea that a complex, multi-marker panel would automatically improve diagnosis was not supported by the data in this setting. The researchers suggest that the other markers, particularly KLK2 and CRP, might still be valuable as follow-up tests for men whose PSA results fall into a confusing middle range, but they are not a replacement for the standard test in cases where the PSA is already very high. The work highlights that in medical science, adding more data does not always mean getting a clearer picture; sometimes, the simplest signal is the most accurate one, especially when the disease has already made its presence known.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.